TenNor Therapeutics (Suzhou) Ltd
Biotechnology · SUZHOU, F4
BiotechnologySEC Form D
TenNor Therapeutics (Suzhou) Ltd filed a Form D with the U.S. Securities and Exchange Commission on May 26, 2026, reporting $14,699,667 raised.
Incorporated in China and based in SUZHOU, F4, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that TenNor Therapeutics (Suzhou) Ltd has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- Zhenkun MaExecutive Officer · Director
- Gaoguang SongDirector
- Michael James BakesDirector
- Wai Kong LeeDirector
- Lin NiDirector
- Leping LiDirector
- Jie BiExecutive Officer
- Guozhu GengExecutive Officer
- Jing ChenExecutive Officer
- Yinjiao YuExecutive Officer
- Rongping ChenExecutive Officer
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$10.0MRaised